Ocular Therapeutix Inc. logo

Ocular Therapeutix Inc.

OCUL | NASDAQ
Chart Builder DCF Calculator
$10.50
+$0.51 (+5.11%)
At close: Sep 22, 2026, 4:00 PM ET
$10.45
-$0.05 (-0.48%)
After-hours: Sep 22, 2026, 7:30 PM ET

Company Profile

Ocular Therapeutix, Inc. is a biopharmaceutical company specializing in the creation, advancement, and commercialization of ophthalmic treatments. Their innovative approach leverages a proprietary bioresorbable hydrogel technology to address a range of eye diseases and conditions. The company currently offers two key products: ReSure Sealant, an ophthalmic device designed to prevent fluid leakage from corneal incisions after cataract surgery, and DEXTENZA, a dexamethasone-based ophthalmic insert used to manage post-surgical inflammation and pain in the eye, as well as to treat allergic conjunctivitis. In addition to their commercial offerings, Ocular Therapeutix is actively developing several product candidates in various clinical stages, including: OTX-TKI, an axitinib intravitreal implant in Phase 1 clinical trials for wet age-related macular degeneration (AMD) and other retinal diseases. OTX-TIC, a travoprost intracameral implant, currently in Phase 2 studies for open-angle glaucoma and ocular hypertension. OTX-CSI, a cyclosporine intracanalicular insert that has successfully completed Phase 2 clinical trials for dry eye disease. OTX-DED, a dexamethasone intracanalicular insert undergoing Phase 2 evaluation for the temporary relief of dry eye symptoms. Strategic partnerships are also a significant part of Ocular Therapeutix's operations. This includes a collaboration with Regeneron Pharmaceuticals, Inc. focused on developing and commercializing products that combine Ocular Therapeutix's sustained-release hydrogel technology with Regeneron's large molecule VEGF-targeting compounds for retinal disease treatment. Another partnership with AffaMed Therapeutics Limited covers the development and commercialization of DEXTENZA and OTX-TIC. Additionally, a discovery-focused collaboration with Mosaic Biosciences aims to pinpoint novel targets and therapeutic agents for dry age-related macular degeneration (dAMD). Established in 2006, Ocular Therapeutix, Inc. maintains its headquarters in Bedford, Massachusetts.

Key Executives

Name Position
Pravin U. Dugel Executive Chairman, President & Chief Executive Officer
Donald Notman Jr. Chief Operating Officer (Leave of Absence)
Todd Anderman Chief Legal Officer & Corporate Secretary
Jason Robins CFO & Principal Accounting Officer
Jeffrey S. Heier Chief Scientific Officer
Nadia K. Waheed Chief Medical Officer
Peter K. Jarrett Chief Technical Officer
Sanjay Nayak MBBS Chief Strategy Officer
Steve Meyers Chief Commercial Officer
William S. Slattery Jr. Vice President of Investor Relations

Latest SEC Filings

Date Type Title
Sep 02, 2026 4 Filing
Aug 26, 2026 4 Filing
Aug 26, 2026 4 Filing
Aug 26, 2026 4 Filing
Aug 26, 2026 4 Filing
Aug 03, 2026 S-8 Filing
Aug 03, 2026 10-Q Quarterly Report
Aug 03, 2026 8-K Current Report
Jul 29, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Jun 18, 2026 4 Filing
View All SEC Filings
Ocular Therapeutix Inc.
Ocular Therapeutix Inc. logo
Country United States
IPO Date Jul 24, 2014
Industry Biotechnology
Sector Healthcare
Employees 325
CEO Pravin U. Dugel

Contact Details

24 Crosby Drive Bedford, Massachusetts 01730 United States

Stock Details

Ticker Symbol OCUL
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001393434
CUSIP Number 67576A100
ISIN Number US67576A1007
SIC Code 2834

© 2026 bestshares.com. All rights reserved.